Core Insights - ImmunityBio, Inc. (IBRX) shares surged 41.9% following the European Commission's conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) [1][5] Regulatory Approval - Anktiva plus BCG is the first immunotherapy authorized in Europe for the NMIBC indication, now cleared in 33 countries across four regulatory jurisdictions, including the US, EU, UK, and Saudi Arabia [2] - The approval was anticipated as the European Medicines Agency's advisory committee had previously recommended marketing authorization for this combination therapy [3] Clinical Efficacy - The approval is supported by the phase II/III QUILT-3.032 study, which showed a 71% complete response rate among 100 adults with BCG-unresponsive NMIBC CIS [6] - Among responders, 66% maintained a complete response at 12 months and 42% at 24 months, with a median duration of complete response of six months [6] Safety Profile - Most treatment-related adverse events reported in the QUILT-3.032 study were mild to moderate, with common adverse reactions including dysuria, hematuria, and urinary tract infections [7] Market Context - Bladder cancer is a significant health issue in the EU, with about three-quarters of diagnoses being NMIBC, and treatment options for BCG-unresponsive cases have been limited [8] - The broader availability of BCG in Europe, with approximately six approved strains, supports combination treatment approaches [9] Ongoing Requirements - ImmunityBio is required to submit long-term follow-up results from ongoing studies to confirm Anktiva's safety and effectiveness, with the authorization subject to annual renewal [4][5]

Core Viewpoint - Veru Inc. is advancing its clinical programs for innovative treatments targeting cardiometabolic and inflammatory diseases, with a focus on the upcoming presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company's drug development pipeline includes two late-stage novel small molecules: enobosarm and sabizabulin [3] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance weight reduction when combined with GLP-1 RA drugs, aiming for more selective fat loss while preserving lean mass [4] - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when used with semaglutide, led to greater fat loss while preserving lean mass and physical function in older patients [4] - The study involved 168 older patients (≥60 years) and showed that while weight loss was similar across treatment groups, the preservation of lean mass is expected to lead to increased energy expenditure and further weight reduction in longer studies [4] Planned Phase 2b PLATEAU Clinical Study - The upcoming Phase 2b PLATEAU clinical trial will evaluate the effects of enobosarm 3 mg on various health metrics in approximately 200 older patients (age ≥ 65) with obesity [5] - The primary efficacy endpoint is the percent change in total body weight at 68 weeks, with an interim analysis planned at 34 weeks [5] - The study aims to assess the ability of enobosarm to overcome weight loss plateaus in patients receiving GLP-1 RA treatment, with a focus on preserving muscle mass and physical function [6]

Core Insights - Artiva Biotherapeutics, Inc. has appointed Elaine Sorg to its Board of Directors, bringing over 35 years of experience in the biopharmaceutical industry, particularly in immunology therapies [1][2] - The company is preparing to share clinical activity data from its AlloNK regimen for rheumatoid arthritis and engage with the FDA for a registrational trial, indicating a significant phase in its development [2] - AlloNK is positioned as a potentially transformative treatment for autoimmune diseases, with a focus on B-cell depletion and improved efficacy compared to existing therapies [2][4] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers, with its lead program being AlloNK, a non-genetically modified NK cell therapy [4][5] - The company was founded in 2019 as a spin-out from GC Cell, acquiring exclusive worldwide rights to NK cell manufacturing technology [4] Leadership Experience - Elaine Sorg has held senior executive roles at major pharmaceutical companies, including AbbVie and Eli Lilly, where she was instrumental in the commercialization of key immunology products [2][3] - Her experience includes leading U.S. commercialization efforts for a broad portfolio of medicines and overseeing major autoimmune disease brands [2][3]

MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (FIL), Lisbon ...

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and yo ...

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options Pre-clinical analysis of tivoxavir marboxil tablets demonstrated significantly increased exposure compared to a prototype formulation with predicted 28-day protection in humans from ...

MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 25-26, 2026 (Virtual)Presentation: Thursday, February 26th at 12:40 p.m. ET T ...

Core Insights - Praxis Precision Medicines has submitted two New Drug Applications (NDAs) for ulixacaltamide and relutrigine, targeting essential tremor and developmental and epileptic encephalopathies respectively, with pre-launch activities expected to accelerate through 2026 [1][3][4] - The company reported a significant increase in cash and investments, totaling $926 million as of December 31, 2025, and net proceeds of $621 million from a public offering in January 2026, which will fund operations into 2028 [10][11] Company Updates - The CEO highlighted a successful fourth quarter with multiple clinical and regulatory advancements, positioning the company for a transition into a commercial entity pending positive reviews of the NDAs [3] - Praxis is scaling its commercial organization and preparing for the launch of ulixacaltamide and relutrigine, including building inventory and initiating disease awareness campaigns [6][10] Financial Performance - As of December 31, 2025, Praxis reported cash, cash equivalents, and marketable securities of $926.1 million, a substantial increase from $469.5 million in 2024, primarily due to proceeds from a public offering [10] - Research and development expenses for Q4 2025 were $77.5 million, up from $56.3 million in Q4 2024, with total R&D expenses for the year reaching $267.1 million compared to $152.4 million in 2024 [11][12] - The company incurred a net loss of $88.9 million for Q4 2025, compared to a loss of $58.7 million in Q4 2024, and a total net loss of $303.3 million for the year [14][29] Product Development - Ulixacaltamide is the first investigational therapy to show positive results in a Phase 3 program for essential tremor, with Breakthrough Therapy Designation granted by the FDA [4][17] - Relutrigine has been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA, targeting sodium channel modulation for developmental epileptic encephalopathies [5][19] - Vormatrigine, another product in development, is positioned as a best-in-class therapy for focal onset seizures and generalized epilepsy, with topline results expected in 2026 [8][11] Upcoming Milestones - Praxis plans to present results from the Essential3 program at the American Academy of Neurology Annual Meeting in April 2026, which will further support the launch of ulixacaltamide [4][6] - The EMERALD study for relutrigine is progressing well, with full enrollment expected in the second half of 2026, potentially leading to a supplemental NDA submission in 2027 [6][10]

Core Insights - The Meridian Small Cap Growth Fund reported a 0.90% net return in Q4 2025, underperforming the Russell 2000 Growth Index, which returned 1.22% [1] - Small caps achieved an annual return of 12.8% with a 2.2% gain in Q4 2025, indicating a positive overall market performance despite some cooling in sentiment [1] Company Highlights - Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on autoimmune diseases, with its lead drug Obexelimab in Phase 3 trials, potentially launching in 2027 [3] - Zenas BioPharma's stock saw a one-month return of 30.78% and a remarkable 241.61% increase over the past 52 weeks, closing at $26.68 per share with a market cap of $1.432 billion on February 18, 2026 [2][3] - The company has the potential for annual revenues exceeding $1 billion, contingent on successful drug development and regulatory approval [3] Investment Sentiment - Zenas BioPharma is not among the top 30 most popular stocks among hedge funds, with 13 hedge fund portfolios holding its shares at the end of Q3 2025, unchanged from the previous quarter [4] - While Zenas BioPharma is recognized for its potential, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]

Core Insights - Insmed reported total revenues of $606.4 million for the full year 2025, with significant contributions from its products BRINSUPRI and ARIKAYCE [1][2] - The company anticipates full-year 2026 revenues for BRINSUPRI to be at least $1 billion and for ARIKAYCE to be between $450 million and $470 million [1][2] - Insmed's net loss for the fourth quarter of 2025 was $328.5 million, compared to a net loss of $235.5 million in the same quarter of 2024 [2][3] Financial Performance - Total revenues for the fourth quarter of 2025 were $263.8 million, a 153% increase compared to $104.4 million in the fourth quarter of 2024 [2] - ARIKAYCE revenues for the fourth quarter of 2025 were $119.2 million, reflecting a 14% growth year-over-year, while full-year revenues reached $433.8 million, a 19% increase from 2024 [2] - BRINSUPRI generated $144.6 million in the fourth quarter and $172.7 million for the full year 2025, marking its successful U.S. commercial launch [1][2] Research and Development Updates - Insmed is advancing its clinical programs, including the Phase 3 ENCORE trial for ARIKAYCE and additional Phase 3 studies for TPIP in patients with pulmonary conditions [1][2] - The company plans to submit a supplementary new drug application for ARIKAYCE in the second half of 2026, pending positive topline data from the ENCORE trial [1][2] - Insmed is also developing INS1148 and INS1201, targeting various respiratory and genetic diseases, with IND filings expected in 2026 [1][2] Cash Position and Future Guidance - As of December 31, 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company for continued investment in its pipeline [1][2] - The company expects to maintain a focus on commercialization and expansion of its product offerings, particularly BRINSUPRI and ARIKAYCE, throughout 2026 [1][2] - Insmed anticipates that pre-clinical research programs will comprise less than 20% of overall expenditures, indicating a strategic focus on advancing clinical development [2]